Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS. Chris Min K, et al. Among authors: stone ja. Clin Pharmacol Ther. 2019 May;105(5):1234-1243. doi: 10.1002/cpt.1258. Epub 2019 Jan 18. Clin Pharmacol Ther. 2019. PMID: 30347431 Clinical Trial.
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, Petry AS, Ghosh K, Mangin E, DeNoia EP, Wenning LA, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. Among authors: stone ja. J Clin Pharmacol. 2008 Feb;48(2):209-14. doi: 10.1177/0091270007310382. Epub 2007 Dec 12. J Clin Pharmacol. 2008. PMID: 18077730 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. J Clin Pharmacol. 2008 Apr;48(4):418-27. doi: 10.1177/0091270008314467. Epub 2008 Feb 7. J Clin Pharmacol. 2008. PMID: 18258750 Clinical Trial.
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M. Wenning LA, et al. Among authors: stone ja. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279563 Clinical Trial.
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. Stoch SA, et al. Among authors: stone j. Clin Pharmacol Ther. 2009 Aug;86(2):175-82. doi: 10.1038/clpt.2009.60. Epub 2009 May 6. Clin Pharmacol Ther. 2009. PMID: 19421185 Clinical Trial.
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, Stone JA, Chodakewitz JA, Wagner JA, Iwamoto M. Brainard DM, et al. Among authors: stone ja. J Clin Pharmacol. 2011 Mar;51(3):422-7. doi: 10.1177/0091270010367652. Epub 2010 May 10. J Clin Pharmacol. 2011. PMID: 20457591 Clinical Trial. No abstract available.
346 results